journal article·2017-12-11

Absorbable Hemostatic Aggregates

Allen Y. Wang, Joseph Rafalko, Melinda MacDonald, Xintian Ming, Richard Kocharian

Publisher page

Abstract

Topical absorbable hemostats are routinely utilized in surgical procedures to assist in controlling intraoperative bleeding. SURGICEL Original Absorbable Hemostat, one of the most frequently used adjunctive hemostats, is composed of oxidized regenerated cellulose (ORC). We report here that a novel powdered form of ORC, composed of aggregates of ORC fine fibers, provides additional valuable hemostatic performance characteristics and retains the biochemical and bactericidal profile of the parent ORC fabric. The ORC aggregates are more effective in promoting coagulation than their constituent ORC fine fibers because of more favorable surface energetics and surface area. Aggregates with similar particle size distributions that have higher sphericity values exhibit better coagulation efficacy. Finally, ORC aggregates more effectively promote clot formation than starch-based hemostatic particles. The results of this investigation indicate that the efficacy of this novel powdered hemostat is based on its chemical composition, morphology, and particle surface energetics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hemostasis and retained surgical items · Surgical Sutures and Adhesives · Wound Healing and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Preclinical Center of Excellence, Johnson & Johnson Medical Devices Companies, Route 22 West, Somerville, New Jersey 08876-0151, United States

Funding

Johnson and Johnson

References (31)

Show source-provided references
1. 10.1097/01.ta.0000199961.02677.1910.1097/01.ta.0000199961.02677.19 ↗
2. 10.1007/s10570-012-9828-810.1007/s10570-012-9828-8 ↗
3. 10.3109/08941939.2014.94144410.3109/08941939.2014.941444 ↗
4. 10.1016/j.transci.2004.07.00610.1016/j.transci.2004.07.006 ↗
5. 10.1007/s00068-015-0612-y10.1007/s00068-015-0612-y ↗
6. 10.1111/j.1541-4337.2012.00199.x10.1111/j.1541-4337.2012.00199.x ↗
7. 10.1016/j.powtec.2010.05.00610.1016/j.powtec.2010.05.006 ↗
8. Thakur V. K. · 201510.1201/b18390 ↗
9. 10.1097/SLA.0b013e3181c3bcca10.1097/SLA.0b013e3181c3bcca ↗
10. 10.1016/j.juro.2006.07.12810.1016/j.juro.2006.07.128 ↗
11. 10.1016/j.powtec.2013.09.00410.1016/j.powtec.2013.09.004 ↗
12. 10.1016/j.mineng.2014.05.00210.1016/j.mineng.2014.05.002 ↗
13. 10.1007/s11095-014-1414-310.1007/s11095-014-1414-3 ↗
14. 10.1089/10962960332241959910.1089/109629603322419599 ↗
15. 2016
16. USP Monograph 38.http://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_m14210.html.
17. 10.1021/ja01269a02310.1021/ja01269a023 ↗
18. Kiselev A. V. · 196910.1007/978-1-4899-6503-5 ↗
19. Condor J. R. · 1979
20. 10.1016/S0021-9673(00)86810-710.1016/S0021-9673(00)86810-7 ↗
21. 10.1016/j.chroma.2015.11.03310.1016/j.chroma.2015.11.033 ↗
22. 10.1021/ac00220a01110.1021/ac00220a011 ↗
23. 10.1080/0363904070137803510.1080/03639040701378035 ↗
24. 10.1021/la801676n10.1021/la801676n ↗
25. 10.1007/BF0226238510.1007/BF02262385 ↗
26. 10.1016/0021-9797(80)90304-510.1016/0021-9797(80)90304-5 ↗
27. Good R. J. · 2003
28. Van Oss C. J. · 1994
29. Rosina J. · Physiol. Res. · 2007 · 56 · S9310.33549/physiolres.931306 ↗
30. 2011
31. Methods for Determining Bactericidal Activity of Antibacterial Agents; Approved Guideline. Vol.19,No. 18; Document M26-A;Clinical and Laboratory Standards Institute:Wayne, PA, 1999.